High p-Smad2 expression in stromal fibroblasts predicts poor survival in patients with clinical stage I to IIIA non-small cell lung cancer

Abstract

BackgroundIncreasing evidence indicates that the TGFβ/Smad signaling pathway plays a prominent role in tumor initiation, progression, and metastasis. Therefore, we investigate the expression of p-Smad2 in surgical resection specimens from non-small cell lung cancer, and evaluate the prognostic significance of p-Smad2 expression in stromal fibroblasts and cancer cells for patients with clinical stage I to IIIA non-small cell lung cancer.MethodsThe immunohistochemical expression of p-Smad2 was evaluated in 78 formalin-fixed paraffin-embedded surgical resection specimens from clinical stage I to IIIA non-small cell lung cancer. Correlations between p-Smad2 expression and clinicopathologic characteristics were determined by Chi-square test. The prognostic significance of p-Smad2 expression in stromal fibroblasts and cancer cells with regard to overall survival was determined by Kaplan-Meier.ResultsThere were 38.5% (30/78) and 92.3% (72/78) patients with high p-Smad2 expression in stromal fibroblasts and cancer cells, respectively. There was a positive correlation between the p-Smad2 expression level in stromal fibroblasts and the p-Smad2 expression level in cancer cells (χ2 = 4.176, P =0.045). No significant correlation of p-Smad2 expression in stromal fibroblasts or cancer cells with any of clinicopathologic characteristics was found. The 3-year overall survival rates with low and high p-Smad2 expression in stromal fibroblasts were 53.7% and 37.7%, respectively (χ2 = 3.86, P = 0.049). No significant association was found between low and high p-Smad2 expression in cancer cells with respect to overall survival, respectively (χ2 = 0.34, P =0.562).ConclusionsThe results suggested that high p-Smad2 expression in stromal fibroblasts predicted poor survival in patients with clinical stage I to IIIA non-small cell lung cancer.

An individualized prognostic signature and multi-omics distinction for early stage hepatocellular carcinoma patients with surgical resection

“…Besides, MYC had a direct link with SMAD2 which was hypomethylated and overexpressed in the high-risk patients and interacted with 15 DEGs in the sub-network. It is known that the overexpression of SMAD2, a regulator of cell proliferation, apoptosis and differentiation, is correlated with poor survival of gastric carcinoma [ 36 ], gliomas [ 37 ] and non-small cell lung cancer [ 38 ]. Additionally, the overexpression of SMAD2 could be induced by the suppressed activity of PTEN [ 39 ], which was hypermethylated and underexpressed in the high-risk patients.…”

Mutant p53 Promotes Tumor Cell Malignancy by Both Positive and Negative Regulation of the Transforming Growth Factor β (TGF-β) Pathway

“…Consistently, clinical research has found that high p-Smad2 expression in stromal fibroblasts predicted poor survival in patients with clinical stage I to IIIA non-small-cell lung cancer (50), indicating that Smad2 may play an important role in mediating lung cancer metastasis. The association between a high level of p-Smad2 and a malignant phenotype and poor prognosis in patients with advanced carcinoma (51) suggests that targeting mutant p53 may amend the balance between Smad2 and Smad3 signaling for late-stage cancers.…”

Integrated TCGA and GEO analysis showed that SMAD7 is an independent prognostic factor for lung adenocarcinoma

“…[ 32 ] At the same time, in patients with non-small cell lung cancer, high expression of p-SMAD2 is predictive of poor clinical survival. [ 33 ] Like SMAD2, SMAD3 is considered a tumor suppressor. In lung cancer, the deletion of SMAD3 can inhibit the pathway of tumor growth through TGF-β, thereby promoting tumorigenicity.…”